Objective: Due to the global spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), guidance for the use of psychotropic drugs in this context is necessary. We aimed to review clinical evidence regarding the potential toxicity of psychiatric medications in the context of SARS-CoV-2 infection.
Methods: A systematic search for all types of empirical studies and reviews in a broad set of electronic databases and trial registries was conducted up to the 15th of August 2020.
Due to the rapid spread of the novel coronavirus pandemic, a reorganization of the health care sector was needed. Many questions arose concerning the specificity of psychiatric care in this unprecedented situation. In Geneva, Switzerland, the department of psychiatry decided to open a new ward for its infected patients.
View Article and Find Full Text PDFRev Med Suisse
September 2018
Negative symptoms in schizophrenia can be categorized in the symptom-dimensions of apathy (avolition, anhedonia and social withdrawal) and reduced expression (blunted affect and alogia). Based on the strong relevance for the quality of life and functional outcome during the course of an illness, a differentiated diagnostic and therapeutic approach is of high importance. Such a differentiation specifies primary negative symptoms (regarded as an integral part of schizophrenia) and secondary negative symptoms (regarded as a result of positive symptoms, comorbid depression, effects of antipsychotic medication, substance abuse or social deprivation).
View Article and Find Full Text PDFMental illness often emerges in young adulthood, usually before the age of 25 years. Early detection and intervention have a positive impact on the evolution of mental illness and quality of life. Specific interventions for this age group are recommended with a focus on ease of access to health care, adaptation to problems facing the young adult, using an integrated medical psycho-social approach.
View Article and Find Full Text PDF